US Stock market today: Wall Street edges higher as Trump comments jolt Fed outlook, chip stocks rebound sharply after recent slump
US Stock market today: Dow, S&P 500, Nasdaq react as Trump's Iran deadline and Fed rate cut hopes drive market uncertainty-
US stock market today showed mixed signals as Wall Street reacted to two major developments — President Donald Trump's two-week deadline on military action against Iran and renewed expectations for a Federal Reserve interest rate cut by July. As traders returned after the Juneteenth holiday break, markets digested global tensions and economic policy shifts.
The Dow Jones Industrial Average (^DJI) climbed 0.4%, while the S&P 500 (^GSPC) posted a modest 0.2% gain. In contrast, the Nasdaq Composite (^IXIC) dipped slightly below the flatline, reflecting cautious investor sentiment, especially in tech stocks.
Stocks slipped on Friday as investors digested geopolitical tensions, mixed economic signals, and rising trade risks. The S&P 500 fell 0.3% while the Nasdaq Composite shed 0.7%. The Dow Jones Industrial Average hovered near the flatline, adding just 0.2%.
Why are chip stocks under pressure again?
Tech stocks, especially semiconductors, were hit hard after a
Wall Street Journal
report revealed the US is considering revoking key waivers that allow global chipmakers to use American tech in China.
Nvidia (NVDA) slipped over 1%, while Lam Research (LRCX), Applied Materials (AMAT), TSMC (TSM), and Broadcom (AVGO) each dropped between 2% and 4%. The move signals a potential intensification in the US-China tech war, adding a fresh layer of uncertainty for the sector.
Live Events
Circle extends rally on crypto optimism
Amid the market gloom, crypto firm Circle (CRCL) surged another 13% to trade near $227 following a 30% rally earlier in the week. The bullish momentum was fueled by the Senate's passage of the GENIUS Act, laying a regulatory framework for stablecoins.
Seaport Research Partners rated Circle a 'Buy' with a $235 price target, calling it a top-tier disruptor poised to benefit from global stablecoin adoption.
Accenture, Kroger, CarMax in the earnings spotlight
Accenture (ACN)
tumbled 6% as bookings fell 6% YoY to $19.7 billion, despite revenue and earnings beating estimates. The firm is grappling with slower federal contract activity under Trump's spending cuts.
Kroger (KR)
jumped nearly 9% after raising its full-year sales outlook, though it kept profit guidance unchanged amid persistent consumer caution.
CarMax (KMX)
rallied over 6% following strong earnings and revenue growth, driven by a 5.8% jump in used car sales.
What's the impact of 'triple witching' on stocks?
Wall Street is also bracing for potential volatility following today's 'triple witching' — the quarterly expiration of $6.5 trillion in stock options, index options, and futures contracts. While the event itself was relatively calm, it may open the door for sharper market swings next week as traders reset positions.
Key Market Movers (as of 11:15 AM ET):
S&P 500 (GSPC):
-0.3%
Nasdaq Composite (IXIC):
-0.7%
Dow Jones (DJI):
+0.2%
Crude Oil (CL=F):
+0.16% to $75.26
Circle (CRCL):
+13.63% to $226.76
Accenture (ACN):
-6.05%
Kroger (KR):
+8.70%
CarMax (KMX):
+6.12%
Why is Trump's two-week Iran deadline rattling investors?
President Trump has imposed a two-week window to decide whether the US will directly engage in the ongoing Israel-Iran conflict, as announced via the White House press secretary on Thursday. The market response to this geopolitical news was immediate, with investors growing uneasy over the potential for broader Middle East instability and its impact on oil prices, defense stocks, and global trade.
Although this deadline adds a layer of geopolitical pressure, it also offers a brief diplomatic window. European foreign ministers from France, the UK, and Germany are holding critical talks with Iranian officials in Geneva, hoping to convince Iran to return to negotiations. However, Iran's president swiftly rejected any such efforts on Friday, dampening hopes for a quick resolution.
Could July be the turning point for Fed rate cuts?
Amid these global concerns, Federal Reserve Governor Chris Waller on Friday suggested that interest rate cuts as early as July are not off the table. Waller pointed to recent inflation data that appears relatively tame — even after Trump's introduction of new tariffs — as a reason to consider easing policy.
Although the Federal Reserve chose to hold rates steady this week, Chair Jerome Powell emphasized a cautious approach, stating the central bank is 'not rushing' to cut. This led President Trump to criticize the Fed again, highlighting the friction between the White House and monetary policymakers.
Waller's remarks nudged up the market's expectations for a rate cut in July, though according to CME Group data, most traders still believe a cut is more likely in September.
What does the market reaction say about investor sentiment?
The stock market's mixed movement reflects a blend of optimism about potential rate cuts and fear over geopolitical escalation. The Dow's rise suggests investors are leaning into more traditional, stable sectors, while the Nasdaq's weakness shows caution in higher-risk tech names.
Market analysts say investors are balancing two key themes: one, the possibility of lower borrowing costs that could support growth and equity valuations; and two, the real-world risks of a US-Iran confrontation that could disrupt markets globally.
How are Trump's tariffs influencing the Fed's outlook?
Trump's recent move to reintroduce tariffs on several key goods has created new complications for the Fed. While tariffs often stoke inflation, current data hasn't shown a sharp uptick, giving the Fed more flexibility. That said, if trade tensions escalate or if tariffs weigh on consumer spending, the case for a rate cut could strengthen.
Waller highlighted that inflation indicators are 'coming down slightly,' despite the added pressure from tariffs. This nuance could be a key part of the Fed's July policy discussions — particularly if Trump's foreign policy developments intensify economic uncertainty.
What should investors watch for next?
Looking ahead, markets will closely track:
Any statements from the Trump administration regarding the Iran deadline
Progress in the European diplomatic talks with Iran
Key economic data releases including inflation and jobless claims
Comments from other Fed officials, which may further guide rate expectations
With the Middle East situation evolving and economic policy still in flux, volatility could remain elevated in the short term.
As the US stock market today reacts to President Trump's Middle East stance and hints of a July Federal Reserve interest rate cut, investors are navigating a delicate balance of political risk and economic hopes. With fresh diplomatic efforts underway and the Fed keeping all options open, the next two weeks could be pivotal in shaping market direction.
FAQs:
Q1.
What did President Trump announce about the US-Iran conflict?
A1.
He set a two-week deadline to decide on possible US military action.
Q2.
Will the Federal Reserve cut interest rates in July?
A2.
Fed officials hinted it's possible if inflation stays low.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
14 minutes ago
- Time of India
Why UK's F-35 still stranded in India, defence sources explain
Why UK's F-35 still stranded in India, defence sources explain Modi-Trump presser: US to sell F-35 stealth fighter jets, India ready for deeper cooperation US F-35 Jets: A game changer for IAF? All you need to know about fighter jets No formal acquisition for F-35 aircraft as yet: MEA spokesperson Randhir Jaiswal Air India Express flight makes emergency landing in Trichy after mid-air scare Aero India'25 to showcase aviation giants from IAF's CATS warrior, to US F-35, watch! MiG-29 fighter jet crashes near Agra after mid-air system glitch; pilot ejects to safety Uttarakhand airlift failure: Chopper falls off mid-air amidst an airlift by Indian army's MI-17 helicopter
Mint
27 minutes ago
- Mint
Four Indian pharma stocks that may be hit by US pharma tariff threat
Indian pharma stocks took a beating on Tuesday, 17 June, after US President Donald Trump said tariffs on pharmaceutical imports are coming 'very soon." His comments sent shockwaves across the market, dragging the Nifty Pharma index down by over 2% intraday. It was the worst-performing sector of the day. This isn't the first time Trump has hinted at such a move. He had dropped clues back in April, but this latest announcement has added urgency and concern. The Indian pharma industry, which relies heavily on exports to the US for generics and speciality drugs, is now facing concerns over potential revenue disruptions. Any disruption in trade or pricing could have a direct impact on revenues and margins. In this article, we take a look at five Indian pharmaceutical companies that could be the most affected by the proposed US tariffs. #1 Granules India Granules India has a presence across the pharmaceutical manufacturing value chain, including active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediaries (PFIs) and finished dosages (FDs). It produces and supplies paracetamol, metformin, guaifenesin, and methocarbamol APIs. It has over 10 manufacturing facilities, approximately eight of which are located in India and two in the US. The company sells its products in global markets, including the United States of America, Canada, Latin America, Europe, Asia Pacific, and India. As per the FY24 annual report, 66% of Granules India's total revenue came from North America. This dependence has only deepened in recent quarters with the US market contributing 79% of revenue in the March 2025 quarter, according to the latest investor presentation. Data Source: Earnings Presentation FY25 and Q4 FY25 Given this significant exposure, any tariff-related cost increases could affect both the company's topline and margins. On 17 June 2025, executive director Priyanka Chigurupati said that the company is currently in the final stages of completing remediation work at its Gagillapur facility. It expects this process to wrap up in the next few months, after which a USFDA re-inspection is anticipated. Once this hurdle is cleared, Granules is aiming to launch 11 pending products in the US market, which were temporarily held back during the compliance phase. Production had been scaled down to prioritise remediation, but the company is now preparing to ramp up volumes again as operations stabilise. It's also working on its first major oncology product launch in the US, expected around FY28. To support its future growth strategy, the company is prepping its Genome Valley facility to meet upcoming USFDA and European audits. #2 Gland Pharma Gland Pharma has become a leader in generic injectables. Its presence spans 60 countries, including the US, Europe, Canada, and Australia. The company's business model primarily involves business-to-business, which contributes 98% of its revenue. It provides contract development, dossier compilation, and technology transfer services. The balance comes from business to consumer. Geographically, the company has a strong presence in the US, which contributes 54% of its revenue. Its revenue in the region has grown from ₹2,585 crore in FY22 to ₹3,037 crore in FY24. This makes the company vulnerable to tariffs. Recently, Gland Pharma received approval from the US Food and Drug Administration (US FDA) for Angiotensin II Acetate Injection. Since the company is the first to submit for exclusivity, it qualifies for 180 days of exclusivity for the generic drug. #3 Aurobindo Pharma Aurobindo Pharma has built a strong presence across more than 150 countries, manufacturing generic formulations, APIs, and injectables. It's the largest generic drug company in the US and ranks among the top 10 generic players in eight European countries. That's where the concern comes in. According to its FY24 annual report, half (48%) of Aurobindo's revenue comes from the US. Data Source: Aurobindo Pharma Annual Report 2023-24 As per the company's investor presentation in March 2025, it holds the top spot in the US in terms of oral solids prescription volume, commanding a 10.5% market share in the September 2024 quarter. So, when talk of new US tariffs on pharma imports hits the headlines, Aurobindo's heavy exposure naturally makes the stock vulnerable to a fall. On 16 June 2025, the company announced the incorporation of a new wholly owned subsidiary, Cresedemo Pharma LLC, in the US. This move aims to further strengthen its US pharma business. While the new entity signals Aurobindo's long-term commitment to the US market, the proposed tariffs could present near-term headwinds for the company. Looking ahead, Aurobindo is placing a big bet on the future of biosimilars. With 14 promising products currently in the pipeline, the company is eyeing a massive US$ 50 bilion+ market opportunity. If things go as planned, this could open up an exciting new growth path and offer some much-needed cushion against any potential policy shocks like the proposed US tariffs. Also Read: India seeks financial details of pharmaceutical marketing practices, industry caught in a bind #4 Dr Reddy's Laboratories Dr Reddy's Lab is one of India's largest pharmaceutical firms in the country. The company manufactures a wide range of pharmaceuticals with expertise spanning several therapeutic areas. Through its step-down subsidiary Aurigene Pharmaceutical Services Ltd (APSL), it's making strong strides in the CDMO space. APSL acts as a comprehensive Contract Research, Development, and Manufacturing Organization (CRO/CDMO), offering end-to-end solutions to global pharmaceutical and speciality companies. It has cGMP manufacturing facilities in the UK, Mexico, USA, and India, enabling it to serve a global clientele. Despite this global footprint, a large chunk of Dr Reddy's revenue still comes from the US. Also, the latest investor presentation of Q4FY25, shows 42% of the total revenue from the US market. This heavy dependence on the US leaves the company exposed to the potential impact of new tariffs. In response to increasing tariff speculation, the company has indicated a desire to consider local manufacturing in the US, through acquisitions. This will not only help reduce the risk of import duties but will also deepen its foot in one of its most important markets. Meanwhile, Dr Reddy focuses on maintaining its growth. The company plans to launch 15-20 new products in the US every year. Also Read: Dr. Reddy's focused on securing supply chains amid US tariff uncertainty Conclusion While the possibility of imports has rattled the sector, it's important to take a balanced view before making investment decisions. There's no denying that companies with high revenue exposure to the US, like Aurobindo Pharma, Granules India, and Dr Reddy's could face near-term challenges if such tariffs are implemented. Margins may come under pressure and growth plans might require changes. However, the long-term fundamentals of India's pharmaceutical industry remain strong. The government is actively supporting the sector through key initiatives such as the Production Linked Incentive (PLI) Scheme for Pharmaceuticals, Promotion of Bulk Drug Parks, Pharmaceutical Technology Upgradation Assistance Scheme (PTUAS), and the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP), which aims to make quality medicines accessible at affordable prices. Moreover, according to a recent EY-FICCI report, the Indian pharmaceutical market is poised to reach a value of around $130 billion by 2030, signalling strong growth potential. It's important to conduct thorough research on financials and corporate governance before making investment decisions, ensuring they align with your financial goals and risk tolerance. Happy Investing. Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. This article is syndicated from
Indian Express
41 minutes ago
- Indian Express
Delhi must underline for Washington the grave dangers of Asim Munir's vision of Pakistan
In 2018, in his first term, US President Donald Trump had spelt out, in his typically blunt style, the sense that Rawalpindi and Islamabad had taken advantage of Washington: 'The United States has foolishly given Pakistan more than 33 billion dollars in aid over the last 15 years, and they have given us nothing but lies & deceit, thinking of our leaders as fools… they give safe haven to terrorists'. This week, he said: 'I love Pakistan'. It would be simplistic to view the unprecedented lunch meeting at the White House between Trump and General Asim Munir — the first time a military leader who is not head of state in Pakistan has been accorded the honour — as a major u-turn. Indeed, India-US ties have been steadily deepening over the last three decades, based on a convergence of economic and strategic interests and shared values, even as the US-Pakistan relationship has grown more volatile. That said, the current moment in international relations is one of flux and Delhi must tread carefully. The Pahalgam attack underscored the grave national security threat that Pakistan-sponsored terrorism continues to present for India. With Operation Sindoor, Delhi has made it clear to both Rawalpindi and the world that it will pierce the shield of 'proxies' and not give in to Pakistan's nuclear blackmail. India has raised the costs of terror in order to ensure that such attacks on its soil are not carried out with impunity. Communicating the new normal it has etched with Pakistan after Pahalgam to its friends abroad is Delhi's challenge. To be sure, Delhi cannot control who Trump chooses to engage, and for what reasons. Pakistan's geography — it shares a 900-km border with Iran — may make it an attractive tactical partner for the US in the current Israel-Iran war. There is speculation that Pakistan's rolling out the red carpet for the privately-owned US cryptocurrency firm, World Liberty Financial (WLF), may have helped ingratiate Munir to the White House — Donald Trump Jr has close ties with WLF. A White House spokesperson has claimed that Munir has proposed Trump for the Nobel Peace Prize for his self-proclaimed role — firmly denied by India — in the post Op Sindoor cessation of hostilities. For India, though, the question is less why the Munir-Trump meeting, and more about how to ensure that the red lines it has laid down are respected, including by the US. Just a fortnight before terrorists killed 26 people in Pahalgam after confirming their religion, Munir had reiterated some of the nastiest tropes of the two-nation theory. He called Kashmir Pakistan's 'jugular vein', and reduced the complex and layered identities of the Subcontinent's people to their religion. It is now for Delhi — diplomatically, through the appropriate channels — to remind Washington that Pakistan's Field Marshal is a fundamentalist with an army at his disposal. Delhi has done well so far in standing its ground and making it clear that it will not compromise on its national interest: Even if belatedly, it issued a clear denial of President Trump's claims about mediating the ceasefire. Now, it must underline for Washington the danger that Munir's vision of Pakistan poses for stability in the region and for global order — and why Delhi has drawn some hard red lines.
